Search
Powered By HealthLine
Special Offers
TV Specials
 Learn about an Effective Alzheimer's Medication
 Bipolar Education Health Center
 Osteoarthritis of the Knee Solution Center
 Heartburn Education Center
 Breast Cancer Health Center
 Crohn's Disease Health Center
 Schizophrenia Education Center
Top Features
 Depression
 Schizophrenia
 Breast Cancer
 Bipolar
Resources
Healthscout News
3D Health Animations
Health Videos
Quizzes & Tools
Health Encyclopedia
In-Depth Reports
Library & Communities
News Archive
Drug Library
Find a Therapist
Enter City or Zip Code:
Powered by Psychology Today
Drug Information
 Drug Search
 Drug Interactions
 Image Database
 Pill Identifier
PR Newswire
 Read latest







Channels
Home |  Today | Women| Men| Kids| Seniors| Diseases| Addictions| Sex & Relationships| Diet, Fitness, Looks| Alternative Medicine| Drug Checker
 Printer Friendly  Send to a Friend

Weight-Loss Drug Helps Diabetic Patients

Yet-to-be-approved rimonabant kept blood sugar in check, study found

By Steven Reinberg
HealthDay Reporter


Related Encyclopedia
 border=
Abdominoplasty
Acidophilus
Addison's Disease
Ankle Sprains
More...

Related Healthscout Videos
 border=
Continuous Glucose Monitoring System
Hungry Heart
Power Out Fat
Soy - Many Forms, Many Benefits
More...

Related Animations
 border=
Diabetes
More...

Related Drug Information
 border=
Actonel
Actos
Amaryl
Avandamet
More...

Related News Articles
 border=
U.S. Schools Getting Better at Boosting Kids' Health
FDA Panel Recommends Ban on Cold Medicines for Kids
Health Tip: Risk Factors for Type 2 Diabetes
Pre-Workout Stretching Won't Prevent Sore Muscles
More...

FRIDAY, Oct. 27 (HealthDay News) -- A new drug to help people lose weight, rimonabant (brand named Acomplia), also helps people with type 2 diabetes shed pounds while improving their blood sugar levels, researchers say.

Rimonabant is being tested and is approved in Europe. However, it has not yet been approved for use in the United States. This finding suggests that rimonabant could be used as a new approach for treating diabetes where other drugs have failed.

Text Continues Below



"This is an interesting new class of drugs that probably offers something new and different to people with diabetes," said Dr. Larry Deeb, president of medicine and science at the American Diabetes Association. He was not involved in the research.

The study was funded by Sanofi-Aventis, the maker of rimonabant, and is published in the Oct. 27 online issue of The Lancet.

In the study, Andre Scheen, from the University of Liege, Belgium, and colleagues looked at the effects of rimonabant in over 1,000 patients with poorly controlled type 2 diabetes. All the patients were obese or overweight and had failed treatment with other drugs.

The patients were given a low-calorie diet plan and advised to be more physically active. They were also given rimonabant at a dose of either 5 milligrams or 20 milligrams per day, or a placebo.

After a year, Scheen's team found that patients taking rimonabant lost significantly more weight than those taking the placebo. Patients on placebo lost an average of 1.4 kilograms, compared with 2.3 kilograms for those given 5 milligrams per day and 5.3 kilograms in patients taking 20 milligrams per day. (For conversion, one kilogram is equal to just over 2 pounds.)

In addition, patients taking rimonabant had greater improvement in waist size, blood sugar control, cholesterol, and better appetite control, compared with patients receiving placebo, the researchers report.

Page:  1 | 2 | 3 | Next >>

Copyright © 2006 ScoutNews LLC. All rights reserved.
Last updated 10/27/2006

Related Links
 border=
From Healthscout's partner site on diabetes, MyDiabetesCentral.com
UNDERSTAND: Learn the differences between Type 1 and Type 2
DRUGS: Common drugs used to treat diabetes
DIET: Eating right can save your life!





New Features

New ADHD Site!

SOURCES: Larry Deeb, M.D., president, medicine and science, American Diabetes Association, Alexandria, Va; Julissa Viana, spokeswoman, Sanofi-Aventis, Bridgewater, N.J; Oct. 27, 2006, online edition, The Lancet


About The HealthScout Network Contact Us
Copyright © 2001-2009. The HealthCentralNetwork, Inc. All rights reserved.
Privacy Policy  Terms of Service   Site Map